FibroBiologics, Inc 10-Q for FY2024 Q2

FibroBiologics, Inc. (FBLG)

10-Q 2024-08-07 For: 2024-06-30

Added on April 07, 2026

About this 10-Q

FibroBiologics, Inc filed this 10-Q on August 7, 2024, covering the quarter ended June 30, 2024 (FY2024 Q2).

Headline figures

Quarter ended June 30, 2024, as reported in this filing, compared with the same period a year earlier where the filing states it.

Net income: $898K; compared with a net loss of $2.16M a year earlier
Diluted EPS: $0.03; compared with -$0.08 a year earlier

Search and read filings like this one from Claude or ChatGPT with the SEC filings MCP server →

(Mark One)

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024.

	or

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to

Delaware		86-3329066
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

455 E. Medical Center Blvd, Suite 300 Houston, TX 77598		77598
(Address of principal executive offices)		(Zip Code)

Title of each class:		Trading symbol(s)		Name of each exchange on which registered:
Common Stock, $0.00001 par value		FBLG		The Nasdaq Global Market

Large accelerated filer ☐	Accelerated filer ☐

Non-accelerated filer ☒	Smaller reporting company ☒

	Emerging growth company ☒

PART I — FINANCIAL INFORMATION

Item 1.	Financial Statements (Unaudited)	4

	Condensed Balance Sheets as of June 30, 2024 (Unaudited) and December 31, 2023	4

	Unaudited Condensed Statements of Operations for the three and six months ended June 30, 2024 and 2023	5

	Unaudited Condensed Statements of Changes in Stockholders’ Equity/(Deficit) for the three and six months ended June 30, 2024 and 2023	6

	Unaudited Condensed Statements of Cash Flows for the six months ended June 30, 2024 and 2023	7

	Notes to the Unaudited Condensed Financial Statements	8

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	20

Item 3.	Quantitative and Qualitative Disclosures About Market Risk	27

Item 4.	Controls and Procedures	28

PART II — OTHER INFORMATION

Item 1.	Legal Proceedings	29

Item 1A.	Risk Factors	29

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	29

Item 3.	Defaults Upon Senior Securities	29

Item 4.	Mine Safety Disclosures	29

Item 5.	Other Information	29

Item 6.	Exhibits	30

Signature		31

	●	the timing, progress and results of preclinical studies and clinical trials for our current and future product candidates, including statements regarding the timing of initiation and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available and our research and development programs;

	●	the timing, scope or likelihood of regulatory submissions, filings, and approvals, including final regulatory approval of our product candidates;

	●	our ability to develop and advance product candidates into, and successfully complete, clinical trials;

	●	our expectations regarding the size of the patient populations for our product candidates, if approved for commercial use;

	●	the implementation of our business model and our strategic plans for our business, product candidates and technology;

	●	our commercialization, marketing and manufacturing capabilities and strategy;

	●	the pricing and reimbursement of our product candidates, if approved;

	●	the rate and degree of market acceptance and clinical utility of our product candidates, in particular, and cell therapy, in general;

	●	our ability to establish or maintain collaborations or strategic relationships or obtain additional funding;

	●	our competitive position;

	●	the scope of protection we and/or our licensors are able to establish and maintain for intellectual property rights covering our product candidates;

	●	developments and projections relating to our competitors and our industry;

	●	our estimates regarding expenses, future revenue, capital requirements and needs for additional financing;

	●	the period over which we estimate our existing cash and cash equivalents will be sufficient to fund our future operating expenses and capital expenditure requirements; and

	●	the impact of laws and regulations.

	June 30, 2024			December 31, 2023
	(Unaudited)
Assets
Current assets
Cash and cash equivalents	$	5,973		$	9,163
Prepaid expenses		518			36
Other current assets		18			16
Total current assets		6,509			9,215
Property and equipment, net		799			797
Operating lease right-of-use asset, net		1,604			1,809
Total assets	$	8,912		$	11,821

Liabilities and stockholders’ equity/(deficit)
Current liabilities
Accounts payable and accrued expenses	$	1,208		$	1,444
Parent company payable		—			141
Operating lease liability, short-term		382			362
GEM commitment fee payable		1,941			—
Forward contract liability		1,500			—
Liability instrument		—			7,236
Warrant liability		4,814			—
Short-term note payable		287			—
Total current liabilities		10,132			9,183
Operating lease liability, long-term		1,167			1,385
Total liabilities		11,299			10,568

Stockholders’ equity/(deficit)
Preferred Stock, $0.00001 par value; 8,750,000 Series A Preferred shares authorized; 0 shares and 8,750,000 shares issued and outstanding as of June 30, 2024 and December 31, 2023, respectively		—			—
Preferred Stock, $0.00001 par value; 5,000,000 Series B Preferred shares authorized; 0 shares and 4,171,445 shares issued and outstanding as of June 30, 2024 and December 31, 2023, respectively		—			—
Preferred Stock, $0.00001 par value; 5,000,000 Series B-1 Preferred shares authorized; 0 shares and 89,781 shares issued and outstanding as of June 30, 2024 and December 31, 2023, respectively		—			—
Preferred Stock, $0.00001 par value; 2,500 Series C Preferred shares authorized; 2,500 shares and 0 shares issued and outstanding as of June 30, 2024 and December 31, 2023, respectively		—			—
Preferred Stock, value		—			—
Non-voting Common Stock, $0.00001 par value; 30,000,000 shares authorized; 0 shares and 28,230,842 shares issued and outstanding as of June 30, 2024 and December 31, 2023, respectively		—			1
Voting Common Stock, $0.00001 par value; 100,000,000 shares authorized; 32,719,125 shares and 0 shares issued and outstanding as of June 30, 2024 and December 31, 2023, respectively		—			—
Common Stock, value		—			—
Additional paid-in capital		29,532			25,609
Accumulated deficit		(31,919	)		(24,357	)
Total stockholders’ equity/(deficit)		(2,387	)		1,253
Total liabilities and stockholders’ equity/(deficit)	$	8,912		$	11,821

	2024			2023				2024			2023
	For the Three Months Ended June 30,						For the Six Months Ended June 30,
	2024			2023			2024			2023
Operating expenses:
Research and development	$	975		$	547		$	1,935		$	1,021
General, administrative and other		2,249			1,546			4,739			3,337
Total operating expenses		3,224			2,093			6,674			4,358
Loss from operations		(3,224	)		(2,093	)		(6,674	)		(4,358	)
Other income/(expense):
Change in fair value of liability instrument and warrant liability		5,527			—			2,422			—
Change in fair value of forward contract liability		(1,500	)					(1,500	)		—
Commitment fee expense		—			—			(1,941	)		—
Other income/(loss)		30			(57	)		30			(72	)
Interest income		70			—			110			—
Interest expense		(5	)		(10	)		(9	)		(146	)
Net income/(loss)		898			(2,160	)		(7,562	)		(4,576	)
Deemed dividend		—			—			—			(2,573	)
Net income/(loss) attributable to common stockholders	$	898		$	(2,160	)	$	(7,562	)	$	(7,149	)
Net income/(loss) per share, basic and diluted	$	0.03		$	(0.08	)	$	(0.24	)	$	(0.25	)
Weighted-average shares outstanding, basic and diluted		32,719,125			28,230,842			31,926,444			28,230,842

	Investment		Shares			Amount		Shares			Amount		Shares			Amount		Shares		Amount		Shares			Amount			Shares		Amount		Capital		Deficit			(Deficit)
	Net Parent		Series A Preferred Stock					Series B Preferred Stock					Series B-1 Preferred Stock					Series C Preferred Stock				Non-voting Common Stock						Voting Common Stock				Additional Paid-in		Accumulated			Total Stockholders’ Equity/
	Investment		Shares			Amount		Shares			Amount		Shares			Amount		Shares		Amount		Shares			Amount			Shares		Amount		Capital		Deficit			(Deficit)
Balance – December 31, 2023	$	—		8,750,000		$	—		4,171,445		$	—		89,781		$	—		—	$	—		28,230,842		$	1			—	$	—	$	25,609	$	(24,357	)	$	1,253
Issuance of Series C Preferred Stock		—		—			—		—			—		—			—		2,500		—		—			—			—		—		45		—			45
Conversion to Voting Common Stock		—		—			—		(4,171,445	)		—		(89,781	)		—		—		—		(28,230,842	)		(1	)		32,492,068		—		1		—			—
Cancellation of Series A Preferred Stock upon Direct Listing		—		(8,750,000	)		—		—			—		—			—		—		—		—			—			—		—		—		—			—
Sale of Common Stock		—		—			—		—			—		—			—		—		—		—			—			227,057		—		2,819		—			2,819
Stock-based compensation expense		—		—			—		—			—		—			—		—		—		—			—			—		—		480		—			480
Net loss		—		—			—		—			—		—			—		—		—		—			—			—		—		—		(8,460	)		(8,460	)
Balance (Unaudited) – March 31, 2024		—		—			—		—			—		—			—		2,500		—		—			—			32,719,125		—		28,954		(32,817	)		(3,863	)
Stock-based compensation expense		—		—			—		—			—		—			—		—		—		—			—			—		—		578		—			578
Net income		—		—			—		—			—		—			—		—		—		—			—			—		—		—		898			898
Balance (Unaudited) – June 30, 2024	$	—		—		$	—		—		$	—		—		$	—		2,500	$	—		—		$	—			32,719,125	$	—	$	29,532	$	(31,919	)	$	(2,387	)

	2024			2023
	For the Six Months Ended June 30,
	2024			2023
Cash flows from operating activities
Net loss	$	(7,562	)	$	(4,576	)
Adjustments to reconcile net loss to net cash used in operating activities:
Change in fair value of liability instrument and warrant liability		(2,422	)		—
Change in fair value of forward contract liability		1,500			—
Stock-based compensation expense		1,103			896
Other loss on derivative liability		—			72
Amortization of convertible notes debt discount		—			81
Amortization of operating lease right-of-use asset		205			192
Depreciation expense		72			3
Changes in operating assets and liabilities:
Change in prepaid expenses		(482	)		(39	)
Change in other current assets		(2	)		(284	)
Change in accounts payable and accrued expenses		(236	)		174
Change in commitment fee payable		1,941			—
Change in payable to Parent		(141	)		—
Change in operating lease liability		(198	)		(180	)
Net cash used in operating activities		(6,222	)		(3,661	)

Cash flows from investing activities
Purchases of property and equipment		(74	)		(80	)
Net cash used in investing activities		(74	)		(80	)

Cash flows from financing activities
ROFN Agreement payments to Parent		—			(2,645	)
Repayment and proceeds of note receivable from Parent		—			300
Proceeds from short-term borrowing		574			—
Repayments of short-term borrowing		(287	)		—
Proceeds from issuance of Series B Preferred Stock, net of direct costs		—			14,945
Proceeds from issuance of Series B-1 Preferred Stock, net of direct costs		—			253
Proceeds from issuance of common stock, net of direct costs		2,819			—
Net cash provided by financing activities		3,106			12,853

Net increase/(decrease) in cash and cash equivalents		(3,190	)		9,112
Cash and cash equivalents, beginning of period		9,163			2,266
Cash and cash equivalents, end of period	$	5,973		$	11,378

Supplemental disclosure of cash flow information:
Cash paid for income taxes	$	—		$	—
Cash paid for interest	$	4		$	—

Supplemental disclosure of non-cash investing and financing activities:
Issuance of Series B Preferred Stock for conversion of Notes and accrued interest	$	—		$	5,532
Reclassification of derivative liability for conversion of Notes to Series B Preferred Stock	$	—		$	538

	●	Fair Value of Common Stock—For grants made prior to the Direct Listing on January 31, 2024, the estimated fair value of common stock underlying the Company’s stock-based awards has been determined by the board of directors as of each option grant date with input from management, considering the Company’s most recently available third-party valuations of common stock and the board of directors’ assessment of additional objective and subjective factors that it believed were relevant and which may have changed from the date of the most recent valuation through the date of the grant. These third-party valuations were performed in accordance with the guidance outlined in the American Institute of Certified Public Accountants’ Accounting and Valuation Guide, Valuation of Privately-Held-Company Equity Securities Issued as Compensation (the Practice Aid). For grants made after the Direct Listing, the fair value of common stock underlying stock-based awards is based on the closing price as reported on The Nasdaq Global Market on the date of grant.
	●	Expected Term—The expected term represents the period that a stock-based award is expected to be outstanding. The Company uses the simplified method to determine the expected term, which is based on the average of the time-to-vesting and the contractual life of the option.
	●	Expected Volatility— Due to the Company’s limited operating history and lack of company-specific historical and implied volatility data, the expected volatility is estimated based on the average historical volatilities of common stock of comparable publicly traded entities over a period of time commensurate with the expected term of the stock option grants. The comparable companies are chosen based on their size, stage in the product development cycle, or area of specialty. The Company will continue to apply this process until sufficient historical information regarding the volatility of its own stock price becomes available.
	●	Risk-Free Interest Rate—The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant for zero-coupon U.S. Treasury notes with maturities approximately equal to the expected term of the awards.
	●	Expected Dividend—The Company has never paid dividends on its common stock and has no plans to pay dividends on its common stock. Therefore, the Company used an expected dividend yield of zero.

(in thousands, except share and per share amounts)	2024		2023				2024			2023
	Three Months Ended June 30,					Six Months Ended June 30,
(in thousands, except share and per share amounts)	2024		2023			2024			2023
Numerator:
Net income/(loss)	$	898	$	(2,160	)	$	(7,562	)	$	(4,576	)
Adjustment to numerator for earnings per share:
Deemed dividend		—		—			—			(2,573	)
Net income/(loss) attributable to common stockholders	$	898	$	(2,160	)		(7,562	)		(7,149	)

Denominator:
Weighted-average number of common shares outstanding, basic and diluted		32,719,125		28,230,842			31,926,444			28,230,842
Net income/(loss) per common share attributable to common stockholders, basic and diluted	$	0.03	$	(0.08	)		(0.24	)		(0.25	)

	June 30,			December 31,
(in thousands)	2024			2023
Laboratory equipment	$	871		$	816
Computer equipment, software, and other		47			28
Total property and equipment at cost		918			844
Less: Accumulated depreciation		(119	)		(47	)
Property and equipment, net	$	799		$	797

(in thousands)	Level 1		Level 2		Level 3		Total
	Fair Value Measurement as of June 30, 2024
(in thousands)	Level 1		Level 2		Level 3		Total
Assets:
Cash equivalents	$	5,510	$	—	$	—	$	5,510
Total assets fair value	$	5,510	$	—	$	—	$	5,510

Liabilities:
Liability instrument	$	—	$	—	$	—	$	—
Forward contract liability		—		—		1,500		1,500
Warrant liability		—		—		4,814		4,814
Total liabilities fair value	$	—	$	—	$	6,314	$	6,314

(in thousands)	Liability Instrument			Forward Contract Liability		Warrant Liability
Fair value at December 31, 2023	$	7,236		$	—	$	—
Fair value, beginning balance	$	7,236			—	$	—
Bifurcation of the liability instrument upon Direct Listing		(7,236	)				7,236
Increase in forward contract liability for Draw Down Notice on June 27, 2024		—			1,500		—
Increase in Warrant liability at issuance January 31, 2024		—			—		13,727
Change in fair value of Warrant liability		—			—		(16,149	)
Fair value at June 30, 2024	$	—		$	1,500	$	4,814
Fair value, ending balance	$	—			1,500	$	4,814

(in thousands of dollars)
2024	$	218
2025		488
2026		544
2027		509
Thereafter		—
Total lease payments		1,759
Less: Imputed interest		(210	)
Total lease liabilities		1,549
Less: Current lease liabilities		(382	)
Total non-current lease liabilities	$	1,167

	Stock Options
Unrecognized stock-based compensation expense (in thousands)	$	6,359
Expected weighted-average period compensation costs to be recognized (years)		2.9

	Stock Options		Weighted-Average Exercise Price per Share		Weighted-Average Remaining Contractual Life (years)		Aggregate Intrinsic Value (in thousands)
Outstanding as of December 31, 2023		3,788,500	$	2.31		8.6		10,168
Granted		223,750	$	12.81		9.7		—
Exercised		—	$	—		—		—
Forfeited/Canceled		—	$	—		—		—
Outstanding as of June 30, 2024		4,012,250	$	2.89		8.7		10,168
Exercisable as of June 30, 2024		1,460,809	$	2.31		8.6		3,882

Assumptions:	Six Months Ended June 30, 2024			Six Months Ended June 30, 2023
Risk-free interest rate		4.2 to 4.3%			3.89	%
Expected volatility		97 to 101%			90	%
Expected term (years)		7.0			7.0
Expected dividend		0	%		0	%

	●	advance the development of our lead product candidates through clinical development, and, if approved by the FDA, commercialization;

	●	advance our preclinical development programs into clinical development;

	●	incur manufacturing costs for cell production to supply our product candidates;

	●	seek regulatory approvals for any of our product candidates that successfully complete clinical trials;

	●	increase our research and development activities to identify and develop new product candidates;

	●	hire additional personnel;

	●	expand our operational, financial and management systems;

	●	meet the requirements and demands of being a public company;

	●	invest in further development to protect and expand our intellectual property;

	●	establish a sales, marketing, medical affairs, and distribution infrastructure to commercialize any product candidates for which we may obtain marketing approval and intend to commercialize; and

	●	expand our manufacturing and develop our commercialization efforts.

	●	employee-related expenses, which include salaries, benefits, travel and stock-based compensation for our research and development personnel;

	●	laboratory equipment and supplies;

	●	direct third-party costs such as expenses incurred under agreements with CROs and CDMOs;

	●	consultants that conduct research and development activities on our behalf;

	●	costs associated with conducting preclinical studies and clinical trials;

	●	costs associated with technology; and

	●	facilities and other allocated expenses, which include expenses for rent and other facility related costs and other supplies.

	●	the duration, costs and timing of clinical trials for our current development programs and any further clinical trials related to new product candidates;

	●	the sufficiency of our financial and other resources to complete the necessary preclinical studies and clinical trials;

	●	the acceptance of IND applications for future clinical trials;

	●	the successful and timely enrollment and completion of clinical trials;

	●	the successful completion of preclinical studies and clinical trials;

	●	successful data from our clinical program that supports an acceptable risk-benefit profile of our product candidates in the intended populations;

	●	the receipt and maintenance of regulatory and marketing approvals from applicable regulatory authorities;

	●	establishing agreements with third-party manufacturers for clinical supply for our clinical trials and commercial manufacturing, if any of our product candidates are approved;

	●	the entry into collaborations to further the development of our product candidates;

	●	obtaining and maintaining patent and trade secret protection and regulatory exclusivity for our product candidates; and

	●	successfully launching our product candidates and achieving commercial sales, if and when approved.

	Three Months Ended June 30,						Change Amount
	2024			2023
		(unaudited, in thousands)
Operating expenses:
Research and development	$	975		$	547		$	433
General, administrative and other		2,249			1,546			605

Total operating expenses		3,224			2,093			1,038
Loss from operations		(3,224	)		(2,093	)		(1,038	)
Change in fair value of liability instrument and warrant liability		5,527			—			5,527
Change in fair value of forward contract liability		(1,500	)		—			(395	)
Commitment fee expense		—			—			—
Other income/(loss)		30			(57	)		87
Interest income		70			—			70
Interest expense		(5	)		(10	)		5

Net income/(loss)	$	898		$	(2,160	)	$	4,256

	●	increased personnel related expenses of $0.2 million due to hiring additional research scientists after the three months ended June 30, 2023;

	●	increased research materials and supplies, conferences, and depreciation expenses of $0.2 million due to increased laboratory personnel and preclinical studies; and

	●	increased tissue acquisition costs of $0.1 million.

	●	increased expense of $0.2 million for public company D&O insurance;

	●	increased expenses of $0.2 million for accounting, legal and regulatory costs for our offering in 2024;

	●	increased expenses of $0.2 million for added personnel in 2024;

	●	increased expenses of $0.1 million for legal fees related to patent filings.

	●	increased expenses of $1.0 million for regulatory, legal, accounting, insurance, and marketing expenses related to our direct listing completed in January 2024 and subsequent offering;

	●	increased expenses of $0.4 million for added personnel in 2024;

	●	increased expenses of $0.3 million for legal fees related to patent filings;

	●	decreased expenses of $0.3 million due to timing of an executive bonus in January 2023.

	Six Months Ended June 30,
	2024			2023
	(in thousands)
Net cash used in operating activities	$	(6,222	)	$	(3,661	)
Net cash used in investing activities		(74	)		(80	)
Net cash provided by financing activities		3,106			12,853

Net increase/(decrease) in cash and cash equivalents	$	(3,190	)	$	9,112

	●	the initiation, progress, timeline, cost and results of our clinical trials for our product candidates;

	●	the initiation, progress, timeline, cost and results of additional research and preclinical studies related to pipeline development and other research programs we initiate in the future;

	●	the cost and timing of manufacturing activities, including our planned manufacturing scale-up activities associated with our product candidates and other programs as we advance them through preclinical and clinical development through commercialization;

	●	the potential expansion of our current development programs to seek new indications;

	●	the outcome, timing and cost of meeting regulatory requirements established by the FDA and other comparable foreign regulatory authorities;

	●	the cost of filing, prosecuting, defending, and enforcing patent claims and other intellectual property rights, in-licensed or otherwise;

	●	the effect of competing technological and market developments;

	●	the payment of licensing fees, potential royalty payments and potential milestone payments;

	●	the cost of general operating expenses;

	●	the cost of establishing sales, marketing, and distribution capabilities for any product candidates for which we may receive regulatory approval in regions where we choose to commercialize our products on our own; and

	●	the costs of operating as a public company.

		Incorporation By Reference
Exhibit Number	Exhibit Description	Form	SEC File No.	Exhibit	Filing Date

3.1	Amended and Restated Certificate of Incorporation of the registrant	S-1/A	333-275361	3.1	November 30, 2023

3.2	Amended and Restated Bylaws	8-K	001-41934	3.1	June 27, 2024

4.1	Form of Warrant of FibroBiologics, Inc. issued pursuant to the GEM SPA	S-1/A	333-277019	4.2	March 15, 2024

10.1	Amendment 1 to the Intellectual Property Cross-License Agreement between SpinalCyte LLC and FibroBiologics, Inc., effective as of May 17, 2021.

10.2	Amendment 2 to the Patent Assignment Agreement between SpinalCyte LLC and FibroBiologics, Inc., effective as of May 17, 2021.

31.1	Certification of Principal Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a) promulgated under the Securities Exchange Act of 1934, as amended.

31.2	Certification of Principal Financial and Accounting Officer pursuant to Rules 13a-14(a) and 15d-14(a) promulgated under the Securities Exchange Act of 1934, as amended.

32.1	Certifications of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.*

101.INS	Inline XBRL Instance Document- the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.

101.SCH	Inline XBRL Taxonomy Schema Document.

101.CAL	Inline XBRL Taxonomy Calculation Linkbase Document.

101.DEF	Inline XBRL Taxonomy Definition Linkbase Document.

101.LAB	Inline XBRL Taxonomy Label Linkbase Document.

101.PRE	Inline XBRL Taxonomy Presentation Linkbase Document.

104	Cover Page Interactive Data File (formatted as inline XBRL with applicable taxonomy extension information contained in Exhibits 101.INS, 101.SCH, 101.CAL, 101.DEF, 101.LAB, and 101.PRE).

	FIBROBIOLOGICS, INC.

Date: August 7, 2024	By:	/s/ Mark Andersen
		Mark Andersen Chief Financial Officer (Duly Authorized Officer and Principal Financial Officer)

Docket Number	Country	Appl. No.	Date Filed	Patent No.	Title
AMTK.P0024AU	Australia				TREATMENT OF CACHEXIA USING FIBROBLAST CELLS AND PRODUCTS THEREOF
AMTK.P0024CA	Canada				TREATMENT OF CACHEXIA USING FIBROBLAST CELLS AND PRODUCTS THEREOF
AMTK.P0024EP	European Patent Office				TREATMENT OF CACHEXIA USING FIBROBLAST CELLS AND PRODUCTS THEREOF
AMTK.P0024JP	Japan				TREATMENT OF CACHEXIA USING FIBROBLAST CELLS AND PRODUCTS THEREOF
AMTK.P0024US	United States of America	17/309177	5/3/2021		TREATMENT OF CACHEXIA USING FIBROBLAST CELLS AND PRODUCTS THEREOF

AMTK.P0024US.Pl	United States of America	62/755542	11/4/2018	TREATMENT OF CACHEXIA USING FIBROBLAST CELLS AND PRODUCTS THEREOF
AMTK.P0024WO	Patent Cooperation Treaty	PCT/US2019/059678	11/4/2019	TREATMENT OF CACHEXIA USING FIBROBLAST CELLS AND PRODUCTS THEREOF
AMTK.P0026AU	Australia			REGENERATIVE ABSCOPAL EFFECTS
AMTK.P0026CA	Canada			REGENERATIVE ABSCOPAL EFFECTS
AMTK.P0026EP	European Patent Office	19881814.8		REGENERATIVE ABSCOPAL EFFECTS
AMTK.P0026JP	Japan			REGENERATIVE ABSCOPAL EFFECTS
AMTK.P0026US	United States of America	17/309207	5/6/2021	REGENERATIVE ABSCOPAL EFFECTS
AMTK.P0026US.Pl	United States of America	62/757764	11/9/2018	REGENERATIVE ABSCOPAL EFFECTS
AMTK.P0026WO	Patent Cooperation Treaty	PCT/US2019/060397	11/8/2019	REGENERATIVE ABSCOPAL EFFECTS

/s/ Pete O’Heeron
Name:	Pete O’Heeron
Title:	Chief Executive Officer
Date: 8/5/2024